Trial reportJournal of orthopaedic surgery and research2026
Clinical study on the reduction of perioperative blood loss in primary total hip arthroplasty by local application of hemocoagulase bothrops atrox for injection: a randomized controlled trial.
Trial report in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of the study was to investigate the hemostatic effect of local application of 10 units hemocoagulase bothrops atrox for injection (HBA)during the perioperative period of primary total hip arthroplasty (THA).
methods105 patients who were scheduled to undergo primary THA in the Orthopedics Department of West China Hospital between May 2024 and May 2025 were selected. The participants were randomly divided into the HBA group, the tranexamic acid group(TXA)and the control group, with 35 cases in each. The trial group received an intraoperative local application of 10 units of HBA, the TXA group received 2 g of TXA locally in the surgical area, the control group used an equal amount of normal saline during the operation.Additionally, three groups received 20 mg/kg tranexamic acid intravenously in 100 ml of 0.9% sodium chloride solution over 30 min preoperatively. Various parameters including perioperative hemoglobin decrease, total blood loss, inflammation markers, blood transfusion requirements, VAS scores and Harris Hip Score (HHS) at 1 week, 1 and 3 months, surgical duration, and Compared the adverse events of the three groups of patients.
resultsThere was a significant difference in total blood loss among the three groups of patients. Among them, the HBA group had the least blood loss(P < 0.05). Furthermore, the HBA group demonstrated reduced levels of inflammatory markers CRP and IL-6 on days 1 and 3 post-operation, indicative of a diminished inflammatory response compared to the other groups (P < 0.05). Functional assessments on the 7th day post-surgery revealed significantly lower VAS scores and higher HHS in the HBA group.Notably, No adverse events such as thrombosis were reported in any of the three groups of patients.
conclusionThe localized administration of HBA in conjunction with preoperative intravenous TXA demonstrates a good hemostatic efficacy. Compared with the other groups, the HBA group can reduce the early postoperative inflammatory indicators. LEVEL OF EVIDENCE: Therapeutic Level I.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.